Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.

FERRARI L; GLEMBOTSKY AC; ALVAREZ C; MOLINAS FC; GOETTE NP; MALDONADO AC; KORIN L; HELLER PG; MELA OSORIO MJ; GUTIERREZ MI; LEV PR; MARTA RF

EUROPEAN JOURNAL OF HAEMATOLOGY

WILEY-BLACKWELL PUBLISHING, INC

Lugar: Londres; Año: 2016 vol. 96 p. 435 - 442

0902-4441

BACKGROUND:Anagrelide represents a treatment option for essential thrombocythemia, although its place in therapy remains controversial.AIM:To assess the impact of mutational status in response rates and development of adverse events during long-term use of anagrelide.METHODS:We retrospectively evaluated 67 patients with essential thrombocythemia treated with anagrelide during 68 (4-176) months.RESULTS:Mutational frequencies were 46.3%, 28.3% and 1.5% for JAK2V617F, CALR and MPL mutations. Anagrelide yielded a high rate of hematologic responses, which were complete in 49.25% and partial in 46.25%, without differences among molecular subsets. The rate of thrombosis during treatment was 1 per 100 patient-years, without excess bleeding. Anemia was the major adverse event, 30.3% at 5-year follow-up, being more frequent in CALR+ (p60 months were at higher risk, OR (95%CI) 9.32 (1.1-78.5), p